$IVVD
Invivyd, Inc.

2021 Q3 Form 10-Q Financial Statement

#000095017021001832 Filed on September 20, 2021

View on sec.gov

Income Statement

Concept 2021 Q3 2021 Q2 2020 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $11.05M $7.124M $50.00K
YoY Change 1212.59% 14148.0%
% of Gross Profit
Research & Development $45.37M $35.07M $48.00K
YoY Change 525.65% 72956.25%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $60.42M $44.69M $98.00K
YoY Change 25.85% 45503.06%
Operating Profit -$60.42M -$44.69M -$98.00K
YoY Change 25.85% 45503.06%
Interest Expense $48.00K $23.00K $0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net $43.00K $18.00K $0.00
YoY Change
Pretax Income -$60.38M -$44.67M -$98.00K
YoY Change 25.76% 45484.69%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$60.38M -$44.67M -$98.00K
YoY Change 25.76% 45484.69%
Net Earnings / Revenue
Basic Earnings Per Share -$0.98 -$178.90
Diluted Earnings Per Share -$985.0K -$178.90 -$903.10
COMMON SHARES
Basic Shares Outstanding 111.3M 249.8K
Diluted Shares Outstanding 61.30M 249.8K

Balance Sheet

Concept 2021 Q3 2021 Q2 2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $666.3M $392.5M
YoY Change
Cash & Equivalents $478.3M $392.5M $0.00
Short-Term Investments $188.1M
Other Short-Term Assets $579.0K $261.0K
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $680.2M $396.1M
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $6.115M $1.933M
YoY Change
Total Long-Term Assets $6.115M $1.933M
YoY Change
TOTAL ASSETS
Total Short-Term Assets $680.2M $396.1M
Total Long-Term Assets $6.115M $1.933M
Total Assets $686.3M $398.0M
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $17.56M $10.72M
YoY Change
Accrued Expenses $35.49M $27.18M
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $53.05M $37.90M
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $8.000K $8.000K
YoY Change
Total Long-Term Liabilities $8.000K $8.000K
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $53.05M $37.90M
Total Long-Term Liabilities $8.000K $8.000K
Total Liabilities $53.06M $37.91M
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings -$209.1M -$148.7M
YoY Change
Common Stock $842.3M $4.068M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost) $0.00 $0.00
YoY Change
Treasury Stock Shares $0.00 $0.00
Shareholders Equity $633.2M -$144.6M -$98.00K
YoY Change
Total Liabilities & Shareholders Equity $686.3M $398.0M
YoY Change

Cashflow Statement

Concept 2021 Q3 2021 Q2 2020 Q2
OPERATING ACTIVITIES
Net Income -$60.38M -$44.67M -$98.00K
YoY Change 25.76% 45484.69%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$54.21M -$33.57M $0.00
YoY Change 4643.04%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$188.6M
YoY Change
Cash From Investing Activities -$188.6M
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 328.6M 334.8M 0.000
YoY Change 560.9%
NET CHANGE
Cash From Operating Activities -54.21M -33.57M 0.000
Cash From Investing Activities -188.6M
Cash From Financing Activities 328.6M 334.8M 0.000
Net Change In Cash 85.76M 301.3M 0.000
YoY Change 76.54%
FREE CASH FLOW
Cash From Operating Activities -$54.21M -$33.57M $0.00
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001832038
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
dei Amendment Flag
AmendmentFlag
false
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40703
dei Entity Bankruptcy Proceedings Reporting Current
EntityBankruptcyProceedingsReportingCurrent
true
CY2021Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
111251660
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
392509000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
114988000
CY2021Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3550000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2394000
CY2021Q2 us-gaap Assets Current
AssetsCurrent
396059000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
117382000
dei Entity Registrant Name
EntityRegistrantName
Adagio Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-1403134
dei Entity Address Address Line1
EntityAddressAddressLine1
303 Wyman Street
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 300
dei Entity Address City Or Town
EntityAddressCityOrTown
Waltham
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02451
dei City Area Code
CityAreaCode
781
dei Local Phone Number
LocalPhoneNumber
819-0080
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
dei Trading Symbol
TradingSymbol
ADGI
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
No
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 adgi Deferred Offering Costs Noncurrent
DeferredOfferingCostsNoncurrent
1933000
CY2020Q4 adgi Deferred Offering Costs Noncurrent
DeferredOfferingCostsNoncurrent
0
CY2021Q2 us-gaap Assets
Assets
397992000
CY2020Q4 us-gaap Assets
Assets
117382000
CY2021Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
10716000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
8153000
CY2021Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
27181000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4919000
CY2021Q2 us-gaap Liabilities Current
LiabilitiesCurrent
37897000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
13072000
CY2021Q2 adgi Early Exercise Liability
EarlyExerciseLiability
8000
CY2020Q4 adgi Early Exercise Liability
EarlyExerciseLiability
11000
CY2021Q2 us-gaap Liabilities
Liabilities
37905000
CY2020Q4 us-gaap Liabilities
Liabilities
13083000
CY2021Q2 us-gaap Convertible Preferred Stock Nonredeemable Or Redeemable Issuer Option Value
ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue
504711000
CY2020Q4 us-gaap Convertible Preferred Stock Nonredeemable Or Redeemable Issuer Option Value
ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue
169548000
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2021Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5599240
CY2021Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5599240
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
28193240
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5593240
CY2021Q2 us-gaap Common Stock Value
CommonStockValue
1000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2021Q2 us-gaap Treasury Stock Shares
TreasuryStockShares
0
CY2020Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
22600000
us-gaap Net Income Loss
NetIncomeLoss
-83373000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-98000
CY2021Q2 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.18
us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.66
CY2021Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
249769
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
44691000
us-gaap Operating Expenses
OperatingExpenses
83399000
CY2020Q2 us-gaap Operating Expenses
OperatingExpenses
98000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-44691000
us-gaap Operating Income Loss
OperatingIncomeLoss
-83399000
CY2021Q2 us-gaap Treasury Stock Value
TreasuryStockValue
0
CY2020Q4 us-gaap Treasury Stock Value
TreasuryStockValue
85000
CY2021Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
4067000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
154000
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-148692000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-65319000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-144624000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-65249000
CY2021Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
397992000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
117382000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
35067000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
69204000
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
48000
CY2021Q2 adgi Acquired In Process Research And Development
AcquiredInProcessResearchAndDevelopment
2500000
adgi Acquired In Process Research And Development
AcquiredInProcessResearchAndDevelopment
3500000
CY2021Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
7124000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
10695000
CY2020Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
50000
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-98000
CY2021Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
23000
us-gaap Investment Income Interest
InvestmentIncomeInterest
32000
CY2021Q2 us-gaap Other Nonoperating Gains Losses
OtherNonoperatingGainsLosses
-5000
us-gaap Other Nonoperating Gains Losses
OtherNonoperatingGainsLosses
-6000
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
18000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
26000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-44673000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
125574
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
21250000
CY2021Q2 us-gaap Costs And Expenses Related Party
CostsAndExpensesRelatedParty
247000
us-gaap Costs And Expenses Related Party
CostsAndExpensesRelatedParty
435000
CY2020Q2 us-gaap Costs And Expenses Related Party
CostsAndExpensesRelatedParty
0
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-98000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
-98000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-65249000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
587000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-38700000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-103362000
CY2021Q2 adgi Net Issuance Cost Of Convertible Preferred Stock
NetIssuanceCostOfConvertiblePreferredStock
337000
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
66000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3342000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-44673000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-144624000
us-gaap Profit Loss
ProfitLoss
-83373000
CY2020Q2 us-gaap Profit Loss
ProfitLoss
-98000
us-gaap Share Based Compensation
ShareBasedCompensation
3929000
adgi Non Cash Payments
NonCashPayments
66000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1146000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2159000
CY2020Q2 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
21054000
CY2020Q2 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
96000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-57311000
us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
335264000
adgi Payments Of Initial Public Offering Costs
PaymentsOfInitialPublicOfferingCosts
432000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
334832000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
277521000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
114988000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
392509000
adgi Deferred Offering And Issuance Costs Included In Accounts Payable And Accrued Expenses
DeferredOfferingAndIssuanceCostsIncludedInAccountsPayableAndAccruedExpenses
1602000
us-gaap Net Income Loss
NetIncomeLoss
-83400000
us-gaap Net Income Loss
NetIncomeLoss
-65300000
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-148700000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of the Company’s condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, research and development expenses and related prepaid or accrued costs and the valuation of common stock and resulting stock-based compensation expense. The Company bases its estimates on historical experience, known trends and other market-specific or relevant factors it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates as there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ materially from those estimates or assumptions.</span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company is monitoring the potential impact of the COVID-19 pandemic on its business and consolidated financial statements. The Company is not aware of any specific event or circumstance that would require any update to its estimates or judgments reflected in these consolidated financial statements or a revision of the carrying value of its assets or liabilities as of the issuance date of these condensed consolidated financial statements. These estimates may change as new events occur and additional information is obtained.</span>
CY2021Q2 adgi Fair Value Transfers Between Levels Transfers Amount
FairValueTransfersBetweenLevelsTransfersAmount
0
CY2021Q2 adgi Fair Value Transfers Between Levels Transfers Amount
FairValueTransfersBetweenLevelsTransfersAmount
0
CY2020Q2 adgi Fair Value Transfers Between Levels Transfers Amount
FairValueTransfersBetweenLevelsTransfersAmount
0
CY2021Q2 adgi Prepaid External Research Development And Manufacturing Expense Current
PrepaidExternalResearchDevelopmentAndManufacturingExpenseCurrent
2843000
CY2020Q4 adgi Prepaid External Research Development And Manufacturing Expense Current
PrepaidExternalResearchDevelopmentAndManufacturingExpenseCurrent
2253000
CY2021Q2 adgi Prepaid Compensation And Related Expenses
PrepaidCompensationAndRelatedExpenses
446000
CY2020Q4 adgi Prepaid Compensation And Related Expenses
PrepaidCompensationAndRelatedExpenses
78000
CY2021Q2 us-gaap Other Assets Current
OtherAssetsCurrent
261000
CY2020Q4 us-gaap Other Assets Current
OtherAssetsCurrent
63000
CY2021Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3550000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2394000
adgi Quarterly Fee
QuarterlyFee
1300000
adgi Delivery Fee
DeliveryFee
200000
CY2020Q4 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
63239670
adgi Completion Fee
CompletionFee
200000
CY2021Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
16944484
CY2021Q2 adgi Accrued External Research Development And Manufacturing Expenses Current
AccruedExternalResearchDevelopmentAndManufacturingExpensesCurrent
23643000
CY2020Q4 adgi Accrued External Research Development And Manufacturing Expenses Current
AccruedExternalResearchDevelopmentAndManufacturingExpensesCurrent
3853000
CY2021Q2 us-gaap Accrued Professional Fees Current And Noncurrent
AccruedProfessionalFeesCurrentAndNoncurrent
2262000
CY2020Q4 us-gaap Accrued Professional Fees Current And Noncurrent
AccruedProfessionalFeesCurrentAndNoncurrent
237000
CY2021Q2 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
1272000
CY2020Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
794000
CY2021Q2 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
4000
CY2020Q4 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
35000
CY2021Q2 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
27181000
CY2020Q4 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
4919000
CY2021Q3 adgi Acquired In Process Research And Development Expense
AcquiredInProcessResearchAndDevelopmentExpense
39900000
CY2021Q2 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
8.00
CY2021Q2 adgi Amount Paid For Services
AmountPaidForServices
200000
adgi Amount Paid For Services
AmountPaidForServices
400000
CY2020Q2 adgi Amount Paid For Services
AmountPaidForServices
0
adgi Exercise Fee
ExerciseFee
1000000.0
CY2021Q2 adgi Accrued Upfront Fee
AccruedUpfrontFee
200000
us-gaap Royalty Expense
RoyaltyExpense
0
adgi Acquired In Process Research And Development Expense
AcquiredInProcessResearchAndDevelopmentExpense
200000
CY2021Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
16944484
CY2021Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
16944484
CY2021Q2 us-gaap Preferred Stock Value
PreferredStockValue
504711000
CY2021Q2 us-gaap Preferred Stock Liquidation Preference Value
PreferredStockLiquidationPreferenceValue
505399000
CY2021Q2 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
84722420
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
12647934
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
12647934
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
12647934
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
169548000
CY2020Q4 us-gaap Preferred Stock Liquidation Preference Value
PreferredStockLiquidationPreferenceValue
169900000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
0
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
115000
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
7.61
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
4.61
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P9Y8M12D
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
77563000
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
92500
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
12.80
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
12078560
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
9.26
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P10Y
CY2021Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2968070
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.78
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y9M18D
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
11362000
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
14931630
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.61
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y8M12D
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
77563000
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
14931630
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
6.75
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.96
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.01
CY2021Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
69600000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y9M18D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
1398310
adgi Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Repurchased In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriod
0
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
4194930
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
6943240
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
0
adgi Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Repurchased In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriod
1350000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
5593240
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
0
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3342000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3929000
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021Q2 adgi Net Income Loss Available To Common Stockholders
NetIncomeLossAvailableToCommonStockholders
-44673000
adgi Net Income Loss Available To Common Stockholders
NetIncomeLossAvailableToCommonStockholders
-83373000
CY2020Q2 adgi Net Income Loss Available To Common Stockholders
NetIncomeLossAvailableToCommonStockholders
-98000
CY2021Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
249769
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
125574
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
21250000
CY2021Q2 adgi Net Income Loss Per Share Attributable To Common Stockholders Basic And Diluted
NetIncomeLossPerShareAttributableToCommonStockholdersBasicAndDiluted
-0.18
adgi Net Income Loss Per Share Attributable To Common Stockholders Basic And Diluted
NetIncomeLossPerShareAttributableToCommonStockholdersBasicAndDiluted
-0.66
CY2020Q2 adgi Net Income Loss Per Share Attributable To Common Stockholders Basic And Diluted
NetIncomeLossPerShareAttributableToCommonStockholdersBasicAndDiluted
0
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
103848980
CY2021Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
103848980
CY2020Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5593240
adgi Amount Paid As Pre Paid Funding For Research Plan
AmountPaidAsPrePaidFundingForResearchPlan
1500000

Files In Submission

Name View Source Status
0000950170-21-001832-index-headers.html Edgar Link pending
0000950170-21-001832-index.html Edgar Link pending
0000950170-21-001832.txt Edgar Link pending
0000950170-21-001832-xbrl.zip Edgar Link pending
adgi-20210630.htm Edgar Link pending
adgi-20210630.xsd Edgar Link pending
adgi-20210630ex10_5.htm Edgar Link pending
adgi-20210630ex10_6.htm Edgar Link pending
adgi-20210630ex10_7.htm Edgar Link pending
adgi-20210630ex31_1.htm Edgar Link pending
adgi-20210630ex31_2.htm Edgar Link pending
adgi-20210630ex32_1.htm Edgar Link pending
adgi-20210630ex32_2.htm Edgar Link pending
adgi-20210630_cal.xml Edgar Link unprocessable
adgi-20210630_def.xml Edgar Link unprocessable
adgi-20210630_htm.xml Edgar Link completed
adgi-20210630_lab.xml Edgar Link unprocessable
adgi-20210630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending